A. Unzue; C. Jessen-Trefzer; D. Spiliotopoulos; E. Gaudio; C. Tarantelli; J. Dong; H. Zhao; J. Pachmayr; S. Zahler; E. Bernasconi; G. Sartori; L. Cascione; F. Bertoni; P. Śledź; A. Caflisch; C. Nevado

Journal: RSC Med. Chem.
Year: 2020
Volume: 11
Issue: 8
Pages: 1573-1580
DOI: 10.1039/D0MD00049C
Type of Publication: Journal Article


The X-ray structure of the catalytic domain of the EphA3 tyrosine kinase in complex with a previously reported type II inhibitor was used to design two novel quinoxaline derivatives, inspired by kinase inhibitors that have reached clinical development. These two new compounds were characterized by an array of cell-based assays and gene expression profiling experiments. A global chemical proteomics approach was used to generate the drug-protein interaction profile, which suggested suitable therapeutic indications. Both inhibitors, studied in the context of angiogenesis and in vivo in a relevant lymphoma model, showed high efficacy in the control of tumor size.